Aldeyra Therapeutics to Seek FDA Priority Review of ADX-2191
By Colin Kellaher
Aldeyra Therapeutics Inc. on Thursday said it plans to seek
speedy U.S. Food and Drug Administration approval of its ADX-2191
drug candidate for the treatment of primary vitreoretinal lymphoma,
a rare but potentially fatal retinal cancer.
The Lexington, Mass., biotechnology company said the decision
follows a pre-application meeting with the FDA, adding that it
could submit its application as soon as the end of the year and
that it will request priority review, which would shorten the
agency's review period.
Aldeyra said ADX-2191 could be the first FDA-approved therapy
for primary vitreoretinal lymphoma, which has a median survival of
less than five years.
Write to Colin Kellaher at firstname.lastname@example.org
(END) Dow Jones Newswires
December 01, 2022 08:52 ET (13:52 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.